EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

EEXPAND (phase Ib, dose-finding study) evaluated the starting dose of ruxolitinib in patients with myelofibrosis with baseline platelet counts of 50-99×10(9)/L. The study consisted of dose-escalation and safety-expansion phases. Based on the baseline platelet counts, patients were assigned to stratu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vannucchi, Alessandro M., te Boekhorst, Peter A. W., Harrison, Claire N., He, Guangsheng, Caramella, Marianna, Niederwieser, Dietger, Boyer-Perrard, Françoise, Duan, Minghui, Francillard, Nathalie, Molloy, Betty, Wroclawska, Monika, Gisslinger, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518918/
https://www.ncbi.nlm.nih.gov/pubmed/30442723
http://dx.doi.org/10.3324/haematol.2018.204602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518918/
https://www.ncbi.nlm.nih.gov/pubmed/30442723
http://dx.doi.org/10.3324/haematol.2018.204602

Ejemplares similares